Tóm tắt

Objectives: To assess the anti-cancer effects of 131I-nimotuzumab on immune deficient mouse bearing human laryngeal cancer. Subjects and methods: Three groups of mice bearing human laryngeal cancers were injected via the tail vein by 131I-nimotuzumab, nimotuzumab or 0.9% NaCl, separately. Tumor volume was measured every week. The average survival time and survival rate was calculated for mice in each group. Results: 131I-nimotuzumab could reducing the tumor volume with extending the average life span and increase the survival rate for the mice. Conclusions: 131I-nimotuzumab had the highly anti-cancer effects on immune deficient mice bearing human laryngeal cancer. * Keywords: Larynx cancer: 131I-nimotuzumab; Nude mouse.

Abstract

Objectives: To assess the anti-cancer effects of 131I-nimotuzumab on immune deficient mouse bearing human laryngeal cancer. Subjects and methods: Three groups of mice bearing human laryngeal cancers were injected via the tail vein by 131I-nimotuzumab, nimotuzumab or 0.9% NaCl, separately. Tumor volume was measured every week. The average survival time and survival rate was calculated for mice in each group. Results: 131I-nimotuzumab could reducing the tumor volume with extending the average life span and increase the survival rate for the mice. Conclusions: 131I-nimotuzumab had the highly anti-cancer effects on immune deficient mice bearing human laryngeal cancer. * Keywords: Larynx cancer: 131I-nimotuzumab; Nude mouse.